Model AM-301 - Viral Infections and Allergies
-
Most popular related searches
Preclinical and Clinical Evidence
Preventive use of Bentrio™ reduces SARS-CoV-2 titer by up to 99.4% and 83% for the Alpha and Delta variants, respectively.
Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium model with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 10 minutes prior to inoculation and continued once daily. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >99% for the Alpha and 83% for the Delta variants on Days 3 and 4.
Bentrio™ reduces SARS-CoV-2 titer by up to 92% and 69-85% for the Alpha and Delta variants, respectively, when applied on an already ongoing infection (i.e. used as a treatment).
Mean viral titer in Vero cells over four days following inoculation of human nasal epithelium model with SARS-CoV-2. Treatment with saline solution (control), AM-301 (Bentrio™) or AM-301 without key component (matrix) started 24 hours after inoculation and continued once daily for 4 days. Compared to the saline control group, Bentrio™ achieved a reduction in viral titer of >92% on Day 4 for the Alpha variant and 69 and 83% on days 3 and 4, respectively, for the Delat variant.
Bentrio™ alleviates allergic rhinitis symptoms.
Mean change in the Total Nasal Symptom Score (TNSS) during stay of study participants with history of allergic rhinitis in grass pollen challenge chamber. A single dose of Bentrio™ applied into each nostril prior to entering the chamber provided for a significant reduction in the self-rated TNSS.
Current Clinical Investigations
The NASAR trial, initiated in December 2021, is being conducted during the current pollen season at several study sites in Australia. The trial, which will enroll a total of 100 SAR patients, is designed to compare the safety and efficacy of Bentrio™ against a saline nasal spray.
Customer reviews
No reviews were found for Model AM-301 - Viral Infections and Allergies. Be the first to review!